From 2026, Ireland's Research and Development tax credit stands at 35% of qualifying expenditure, with the first-year instalment threshold raised to EUR 75,000 – meaning companies can access up to that amount in full within the first year of a claim. The credit is governed by TCA 1997 sections 766 and 769G and sits alongside the Knowledge Development Box, which provides an effective 10% rate on qualifying profits for accounting periods commencing before 1 January 2027. For international businesses operating in Ireland, understanding how these two regimes interact – and how to structure a compliant claim – is essential to avoid a costly tax audit and protect any intended benefit.
Legal Basis and the 2026 Changes in Context
The R&D tax credit is one of the most significant incentives available under Irish corporate tax law, embedded in the Taxes Consolidation Act 1997 (TCA 1997). Section 766 governs the core credit mechanism, while section 769G provides the framework for the Knowledge Development Box (KDB). Both regimes have undergone periodic revision by the Irish legislature, with the uplift to 35% and the EUR 75,000 first-instalment threshold representing the most material change for companies planning their 2026 and forward expenditure.
The increase from the prior rate to 35% reflects Ireland's policy intention to reinforce its position as a jurisdiction for substantive research activity, particularly for multinational groups reconfiguring their operations in the context of Pillar Two and global minimum tax rules. Companies engaged in tax structuring in Ireland should evaluate how the credit interacts with their effective tax rate calculations under those rules, as the credit may affect top-up tax liability depending on the group's overall position.
The Knowledge Development Box, at an effective 10% rate, applies to qualifying profits derived from patented inventions, computer programmes and other qualifying assets. Because the KDB accounting period condition – commencing before 1 January 2027 – is time-limited, companies that have not yet initiated a KDB analysis should treat this as an urgent planning matter in the second half of 2026.
Who Qualifies: Core Eligibility Criteria
Eligibility for the R&D credit is not automatic and requires careful attention to both the nature of the activity and the entity undertaking it. The principal requirements are:
- Qualifying activities: The work must constitute systematic, investigative or experimental activities in a field of science or technology, aimed at making an advance in overall knowledge or capability – not merely an advance for the company itself. Routine analysis, quality control, social science research and market research do not qualify.
- In-house vs. outsourced R&D: Companies may claim for expenditure on R&D carried out directly or on qualifying payments to unconnected third parties or universities. Specific rules govern connected-party arrangements and transfer pricing documentation is expected to reflect arm's-length principles where group recharges are involved.
- Accounting period alignment: The credit is claimed in the corporation tax return for the relevant accounting period. The EUR 75,000 first-instalment amount applies to the initial year of a claim cycle, allowing companies to receive that portion promptly rather than waiting for the full credit to feed through the standard three-year carry-forward and repayment process.
- Irish nexus: The R&D activity must be carried out in an EU or EEA state, but the claimant must be within the charge to Irish corporation tax. Foreign companies trading in Ireland through a branch or subsidiary registered with the Companies Registration Office (CRO) can qualify, provided the relevant conditions are met.
- Documentation standard: Revenue Commissioners expect contemporaneous records – project logs, staff time records, technical reports and cost allocations – maintained throughout the period of activity, not reconstructed at the point of filing.
Step-by-Step Procedure for Making a Claim
A well-run R&D credit claim follows a structured process. The sequence below reflects standard practice under current Irish rules; specific deadlines are governed by the corporation tax filing calendar applicable to the company's accounting period end.
- Step 1 – Activity scoping: Identify all projects conducted during the accounting period and assess each against the qualifying activity criteria. This is the stage at which many foreign-owned companies either over-claim (including routine development work) or under-claim (excluding activities that do meet the advance-in-knowledge test). A legal and technical review at this stage reduces tax risk management exposure later.
- Step 2 – Cost capture: Map all direct and indirect costs attributable to qualifying projects: staff salaries (with time apportionment), materials consumed, plant and machinery, and relevant outsourced expenditure. Transfer pricing discipline is particularly important here where costs are recharged within a group.
- Step 3 – Technical narrative: Prepare a written narrative for each qualifying project explaining the scientific or technological uncertainty being addressed, the systematic approach adopted and the advance sought. Revenue auditors focus heavily on this document.
- Step 4 – Financial computation: Calculate the credit at 35% of qualifying expenditure. Determine the EUR 75,000 first-instalment amount if this is the company's initial or renewed claim cycle, and confirm the expected cash-flow profile of the remaining credit.
- Step 5 – Corporation tax return filing: Include the claim in the Form CT1, supported by the technical and financial schedules. The claim is made within the statutory filing window; late claims can result in forfeiture, so calendar management is critical.
- Step 6 – Revenue engagement: Revenue may open an aspect query or a full compliance intervention. Companies should maintain all source documentation and be prepared to explain the technical basis of each project at interview. Engaging legal advisers with experience in tax disputes in Ireland at the first sign of a Revenue challenge is strongly advisable.
If your business is at the scoping or cost-capture stage and would benefit from a structured review, our team is available to assist. Please contact us at info@ferrazwhitmore.com or visit our contacts page.
Illustrative Worked Example
The table below is provided for illustrative purposes only and does not constitute tax advice. Actual credit amounts will depend on the specific facts of each company's expenditure and the applicable rules.
| Item | Amount (EUR) | Notes |
|---|---|---|
| Total qualifying R&D expenditure (accounting period) | 400,000 | Illustrative figure only |
| R&D tax credit at 35% | 140,000 | TCA 1997 s.766; 35% rate from 2026 |
| First instalment (Year 1) | 75,000 | Raised threshold from 2026; receivable in Year 1 |
| Remaining credit (Years 2–3) | 65,000 | Subject to standard carry-forward and repayment rules |
| KDB effective rate on qualifying IP profits (if applicable) | 10% | TCA 1997 s.769G; accounting periods starting before 1 Jan 2027 |
This example is illustrative. It uses only rates confirmed in the Key Facts (35% R&D credit; 10% KDB). It does not represent the outcome of any specific claim and should not be relied upon as a basis for filing.
Realistic Timelines and Cost Drivers
The timeline from first identifying qualifying projects to receiving the initial instalment depends on the company's accounting period end, the completeness of its documentation and whether Revenue raises any queries. Internal preparation – scoping, cost capture and technical narrative drafting – typically takes several weeks for a company undertaking the exercise for the first time. Larger or multi-project claims require proportionally more time.
The principal cost drivers for a well-managed claim are: staff time for documentation and project-by-project analysis; specialist technical input to support the advance-in-knowledge assessment (particularly in software and life sciences claims); legal and tax adviser fees for structuring, documentation review and, where necessary, Revenue correspondence; and ongoing record-keeping infrastructure. Companies that invest in documentation systems from the outset typically face materially lower costs in subsequent years and are better placed to withstand a tax audit.
Anti-avoidance rules under Irish legislation can apply where the primary purpose of an arrangement is the obtaining of the credit rather than genuine R&D activity. Revenue has become more attentive to arrangements involving connected parties, cross-border cost-sharing agreements and group structures where the substance of activity does not match the cost allocation. Robust transfer pricing documentation and a defensible legal structure are essential safeguards.
Common Errors by Foreign Clients and How to Avoid Them
International businesses entering the Irish R&D credit regime for the first time frequently encounter the same set of difficulties. Awareness of these pitfalls in advance can make the difference between a successful claim and a Revenue challenge.
- Including routine product development: Incremental improvements to existing products or processes that do not involve genuine scientific or technological uncertainty do not qualify. Conflating innovation with qualifying R&D is the most common substantive error.
- Inadequate contemporaneous records: Revenue expects documentation created during the project, not assembled retrospectively. Companies that rely on end-of-year reconstruction face credibility challenges in any compliance review.
- Ignoring transfer pricing requirements: Where a foreign parent recharges R&D costs to an Irish entity, or where Irish-generated IP rights are licenced within the group, the arrangement must reflect arm's-length terms. Failure to prepare transfer pricing documentation consistent with OECD guidelines is a recognised audit risk.
- Underestimating CRO and Revenue interaction: Foreign companies operating through Irish branches or subsidiaries must ensure that their corporate records at the CRO are current and that the Irish entity is within the charge to Irish corporation tax on the relevant income. Basic compliance failures at entity level create additional exposure in any Revenue inquiry.
- Missing the KDB window: Because the KDB applies only to accounting periods commencing before 1 January 2027, companies that delay their analysis beyond the current period risk losing access to the 10% rate entirely. The interaction between the R&D credit and the KDB requires careful modelling to optimise the overall position.
- Failure to consider treaty implications: Where a tax treaty applies between Ireland and the investor's home jurisdiction, the characterisation of R&D-related income and the treatment of the credit in the hands of a parent company should be assessed. The rate applicable to any royalty stream or dividend will depend on the applicable treaty, and Irish domestic withholding tax rules must also be considered.
For international groups considering whether to establish or expand R&D activity in Ireland, the interaction between the credit regime and the company's wider structure – including any exposure to the High Court Ireland in a dispute context or regulatory engagement with the Data Protection Commission or Central Bank of Ireland where relevant – should be part of a coordinated legal and tax review. You can explore how these themes connect with broader incentive planning in our guide on Ireland's participation exemption for foreign dividends.
Decision Checklist Before Filing
Before submitting an R&D credit claim, companies should be able to confirm the following:
- Each project included in the claim has been assessed against the qualifying activity criteria and a contemporaneous technical narrative exists for each.
- Staff time records are complete and have been reviewed for accuracy.
- All outsourced and connected-party expenditure is supported by appropriate contracts and, where relevant, transfer pricing documentation.
- The EUR 75,000 first-instalment threshold has been correctly applied based on the company's claim history.
- The claim has been reviewed for anti-avoidance rule exposure, particularly where group arrangements are involved.
- If the KDB is being considered, the accounting period start date has been confirmed as falling before 1 January 2027.
- The corporation tax return is being filed within the statutory deadline for the relevant accounting period.
- Legal and tax advisers have reviewed the claim documentation and are available to respond to any Revenue query.
Sources
- PwC Tax Summaries – Ireland: Corporate Tax Credits and Incentives. Available at: taxsummaries.pwc.com. Facts last verified: 22 September 2026.
- Taxes Consolidation Act 1997, sections 766 and 769G (as amended).
If you are evaluating an R&D credit strategy for an Irish entity or reviewing an existing claim ahead of filing, Ferraz & Whitmore can provide a structured legal and tax analysis tailored to your group's position. Reach us at info@ferrazwhitmore.com or through our contacts page.
Disclaimer: This publication is provided for informational purposes only and does not constitute legal advice. The information herein should not be relied upon as a substitute for professional legal counsel tailored to your specific circumstances. Ferraz & Whitmore assumes no liability for actions taken or not taken based on the contents of this material. For advice regarding your particular situation, please contact info@ferrazwhitmore.com.